Acelyrin Inc (SLRN) - News Archive

ACELYRIN Implements Stockholder Rights Plan in Response to Significant Share AccumulationIn a pivotal development for investors and market watchers, ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company...

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger: A Look at the Combined Entity’s FutureIn the rapidly evolving world of healthcare technology, strategic mergers and acquisitions are piv...

Los Angeles, CA ACELYRIN, INC. (Nasdaq: SLRN), a key player in the late-stage clinical biopharmaceutical landscape, has confirmed the receipt of an unsolicited acquisition proposal from Concentra Biosciences, LLC. The o...

Acelyrin Inc. (NASDAQ: SLRN) is currently facing a turbulent period in its journey through the biopharma landscape. While the company has made strides in developing innovative technology geared towards enhancing patient...

ACELYRIN, INC. Announces Suboptimal Outcomes in Izokibep Uveitis Trial and Market Performance In the ever-evolving sphere of pharmaceutical research, each clinical trial is a stepping stone to potential medical breakthr...

In a significant stride towards advancing the treatment landscape for Thyroid Eye Disease (TED), ACELYRIN, INC. has officially announced the formation of a Scientific and Patient Advisory Board. This coalition is compri...

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and sinus tract formation. The condition can significantly impact patients quality of life due to pain,...

CSIMarket.com Date: 12th October 2023 In a most auspicious development for the field of ophthalmic medicine, ACELYRIN, INC. renowned for its relentless innovation in biopharmaceuticals, hath declared the forthcoming unv...

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024Thyroid eye disease (TED), also known as Graves ophthalmopathy, is an autoimmune condi...

In a recent press release, Acelyrin Inc. announced a significant leadership transition within the company. Mina Kim has been appointed as the new Chief Executive Officer and will also join the Board of Directors. This c...

ACELYRIN, INC. has shared groundbreaking results from their Phase 1/2 proof-of-concept study, showcasing the remarkable efficacy and safety of their innovative subcutaneous anti-IGF-1R therapy, Lonigutamab, in treating...

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisACELYRIN, INC., a leading biopharmaceutical company focused on developing innovative therapi...

ACELYRIN, INC. Boosts Investor Relations with the Appointment of Agnes Lee as Senior Vice PresidentACELYRIN, INC., a leading healthcare company, has announced the appointment of Agnes Lee as Senior Vice President of Inv...

ACELYRIN, INC. Provides Update on Izokibep Clinical Development ProgramLOS ANGELES, Nov. 27, 2023 - ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company specializing in immunology, has recently shared...